ClinicalTrials.gg
CompletedNCT05200936Updated Feb 27, 2026Results posted

Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial

A Phase 2 interventional study of MM120 and Placebo in ADHD and Attention Deficit Disorder, sponsored by Definium Therapeutics US, Inc.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Definium Therapeutics US, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Attention Deficit Disorder with Hyperactivity with a site in Netherlands — 4 open to participants now, 5 under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Netherlands.

Enrollment
25th of 36
53 · median 107
Started
2021
with 2 others
Phase 2
2 of 44
none open now
Registered
35th of 44
by date

Among the 44 studies in Attention Deficit Disorder with Hyperactivity with a site in Netherlands, this one is the 25th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2021, is one of 2 in phase 2, and was the 35th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

4 of the 44 studies in Attention Deficit Disorder with Hyperactivity with a site in Netherlands are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Attention Deficit Disorder with Hyperactivity with a site in Netherlands, or all of them as a file.
02

Study summary

This study measures the safety and efficacy of repeated low dose MM120 as treatment for ADHD in adults: a multi-center, randomized, double-blind, placebo-controlled

Read the detailed description

This study is a multi-center, randomized, double-blind, placebo-controlled Phase 2a study of low dose MM120 (20 μg) compared with a placebo administered for 6 weeks (twice a week on a 3/4-day schedule).

Low dose MM120 (20 μg) is about 20% of the dose typically consumed for recreational psychedelic purposes.

There will be a 1:1 randomization, double-blind, to MM120 or placebo with the aim to reach 26 evaluable patients in each of the 2 arms at Week 6.

03

Conditions studied

  • ADHD
  • Attention Deficit Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female outpatients ≥ 18 and ≤ 65 years of age at Screening
  • Patients with the diagnosis of -5 (DSM-5) ADHD, as determined by clinical evaluation and confirmed by structured interview (MINI).
  • Adequate organ function.
  • Able to understand the study procedures and understand risks associated with the study, and sign written to participate in the study.
  • Must be willing to refrain from more than 6 standard alcoholic drinks a week, more than 10 cigarettes a day, and more than 2 cups of coffee a day throughout the study treatment period (6 weeks) and until the last study visit is complete.

Exclusion criteria

Exclusion Criteria:

  • Past or present diagnosis of a primary psychotic disorder or first degree relative with a psychotic disorder.
  • Past or present bipolar disorder ().
  • Any lifetime history of suicide attempt.
  • Once form is signed, not willing or able to stop any prescription or non-prescription ADHD medications.
  • Use of medication/treatment in the past 30 days.
  • Patients with a positive urine drug screen with the exception of THC or its metabolites.
  • Pregnant or nursing females.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
53 participants (actual)

Study arms

  • Placebo comparator
    Arm 1- Placebo

    A total of 26 patients will receive a placebo identical in appearance to the investigational medicinal product (IMP) administered orally twice weekly (e.g., Tuesday/Friday) for 6 weeks.

    Other: Placebo

  • Experimental
    Arm 2- MM120

    A total of 26 patients will receive 20 μg of MM120 administered orally twice weekly for 6 weeks.

    Drug: MM120

Interventions

  • DrugMM120

    MM120 is a psychedelic drug that can cause intensified thoughts, emotions, and sensory perception. At sufficiently high dosages MM120 manifests primarily visual, as well as auditory, hallucinations.

    Also known as: MM-120, DT120, lysergide tartrate

  • OtherPlacebo

    A treatment which is designed to have no therapeutic value.

06

What researchers measure

Primary outcomes

  1. Change in Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms

    The Adult ADHD investigator symptom rating scale (AISRS) total score consists of 18 items from the original Attention-deficit/hyperactivity Disorder Rating Scale (ADHD-RS). The ADHD-RS includes 9 items that address symptoms of inattention, and 9 items that address symptoms of impulsivity and hyperactivity. Each item is rated from 0 to 3. The AISRS total score can range from 0 to 54. A higher score corresponds to a worse severity of ADHD.

    Time frame: 6 weeks

Secondary outcomes

  1. Changes in Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale (AISRS) Symptoms

    The Adult ADHD investigator symptom rating scale (AISRS) total score consists of 18 items from the original Attention-deficit/hyperactivity Disorder Rating Scale (ADHD-RS). The ADHD-RS includes 9 items that address symptoms of inattention, and 9 items that address symptoms of impulsivity and hyperactivity. Each item is rated from 0 to 3. The AISRS total score can range from 0 to 54. A higher score corresponds to a worse severity of ADHD.

    Time frame: Week 2

  2. Number of Patients Who Experience a Decrease in the Clinical Global Impressions Scale (CGI-S)

    The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness.

    Time frame: Baseline, Week 2, Week 6, Week 10

  3. Change From Baseline in in Clinical Global Impressions Scale (CGI-S)

    The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness.

    Time frame: Baseline, Week 2, Week 6

  4. Adult Attention-deficit/Hyperactivity Disorder Self-reporting Rating Scale (ASRS)

    The Adult Attention-Deficit/Hyperactivity Disorder Self-Reporting Rating Scale (ASRS) is composed of 18 questions, and uses a scale that ranges from 0-4 based on the individuals mark in either the "never, rarely, sometimes, often, very often" column for a possible total score of 72. A higher score corresponds to a worse severity of ADHD.

    Time frame: 6 weeks

  5. Change From Baseline in Connors' Adult ADHD Rating Scale (CAARS)

    The Connors' Adult ADHD Rating Scale (CAARS) Self-Report Long Form is a 66-item measure of ADHD symptom. Responses are scored on a 4-point scale, where 0 = not at all, 1 = just a little, 2 = pretty much, and 3 = very much. Item scores are summed to three main scores which are then transformed using population-derived age- and sex-adjusted norm values to a T-score. A T-score \< 60 indicates no ADHD. A T-score of 60-64 indicates borderline ADHD. A T-score of \> 64 indicates ADHD.

    Time frame: 6 weeks

  6. 5 Dimensions of Altered States of Consciousness Questionnaire (5D-ASC) Scores

    The 5 dimensions of altered states of consciousness (5D-ASC) scale is a visual analog scale (VAS) consisting of 94 items each scored on a 0-100mm VAS extrapolated to 100% scale for quantitative evaluation. These 94 items are categorized into five dimensions: oceanic boundlessness (min:0, max:2700), anxious ego dissolution (min:0, max:2100), visionary destructuralization (min:0, max:1800), auditory alterations (min:0, max:1600), and vigilance reduction (min:0, max:1200). The total score is the sum of all questions and can range from 0 to 9400. Higher scores = more alteration in state of consciousness.

    Time frame: 6 weeks

  7. Mystical Experience Questionnaire 30 Items (MEQ30)

    The Mystical Experience Questionnaire 30 item (MEQ30) is a 30-item questionnaire rated on a six-point scale. The scale has been used to assess mystical experiences in studies using psilocybin and LSD. Higher scores = greater mystical experiences. The total score is expressed as a percentage of the maximum possible score (0 to 100%).

    Time frame: 6 weeks

  8. Summary of Drug Effects Visual Analog Scale (VAS)

    A series of single item visual Analog Scales (VAS) are used repeatedly 0 -6 hours after drug administration: The following 9 items were used in VAS (0-100 mm): "any drug effect", "good drug effect", bad drug effect", "drug liking", "fear", nausea", "alteration of vision", "alteration of sense of time", and "the boundaries between myself and my surroundings seem to blur". VAS scores range from 0 = no effect to 100 = strong effect. The scores for each item are extrapolated to a 100% scale and presented for each time point of assessment.

    Time frame: 6 hours

Other outcomes

  1. Pharmacokinetic Outcomes

    Maximum Plasma Concentration \[Cmax\] of MM-120 in the blood at Week 1 Day 1

    Time frame: 0.5, 1, 2, 3, 4, 6 hours post-dose

  2. Pharmacokinetic Parameters (Cmax)

    Maximum concentration (Cmax)

    Time frame: 0.5, 1, 2, 3, 4, 6 hours post-dose

  3. Pharmacokinetic Parameters (Tmax and t1/2)

    Time to maximum concentration (Tmax), half life (t1/2)

    Time frame: 0.5, 1, 2, 3, 4, 6 hours post-dose

  4. Pharmacokinetic Parameters (AUC0-inf and AUC0-6h)

    Area under the concentration curve from time 0 to infinity (AUC0-inf), Area under the concentration curve from time 0 to 6 hour (AUC0-6h)

    Time frame: 0.5, 1, 2, 3, 4, 6 hours post-dose

07

Results

Posted Apr 13, 2025
Limitations and caveats
Although a multicenter-trial, one site enrolled 95% of participants. Only twice-weekly dose regimen was tested, which may not account for interindividual variability in response. Finally, other outcomes such as emotion regulation were not addressed.

Participant flow

Participant flow — Overall Study
MilestoneArm 2- MM120Arm 1- Placebo
Started2726
Completed2323
Not completed43
Withdrew: Withdrawal by subject22
Withdrew: Lost to follow-up20
Withdrew: Pregnancy01

Outcome measures

PrimaryChange in Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms

The Adult ADHD investigator symptom rating scale (AISRS) total score consists of 18 items from the original Attention-deficit/hyperactivity Disorder Rating Scale (ADHD-RS). The ADHD-RS includes 9 items that address symptoms of inattention, and 9 items that address symptoms of impulsivity and hyperactivity. Each item is rated from 0 to 3. The AISRS total score can range from 0 to 54. A higher score corresponds to a worse severity of ADHD.

Time frame:
6 weeks
Reported as:
Mean · units on a scale
Change in Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms
units on a scaleArm 2- MM-120Arm 1- Placebo
Baseline37.4 ± 6.1137.3 ± 5.24
Week 629.6 ± 8.2729.0 ± 8.47
Statistical analysis
  • Arm 2- MM-120 vs Arm 1- Placebo · Mixed Models Analysis · p = 0.7145 (p-value is 1-sided)
SecondaryChanges in Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale (AISRS) Symptoms

The Adult ADHD investigator symptom rating scale (AISRS) total score consists of 18 items from the original Attention-deficit/hyperactivity Disorder Rating Scale (ADHD-RS). The ADHD-RS includes 9 items that address symptoms of inattention, and 9 items that address symptoms of impulsivity and hyperactivity. Each item is rated from 0 to 3. The AISRS total score can range from 0 to 54. A higher score corresponds to a worse severity of ADHD.

Time frame:
Week 2
Reported as:
Mean · units on a scale
Changes in Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale (AISRS) Symptoms
units on a scaleArm 2- MM-120Arm 1- Placebo
Baseline37.5 ± 5.7636.9 ± 5.10
Week 234.2 ± 6.4932.1 ± 4.96
Statistical analysis
  • Arm 2- MM-120 vs Arm 1- Placebo · ANCOVA · p = 0.9613
SecondaryNumber of Patients Who Experience a Decrease in the Clinical Global Impressions Scale (CGI-S)

The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness.

Time frame:
Baseline, Week 2, Week 6, Week 10
Reported as:
Count of participants · Participants
Number of Patients Who Experience a Decrease in the Clinical Global Impressions Scale (CGI-S)
ParticipantsArm 2- MM-120Arm 1- Placebo
Baseline to Week 2811
Baseline to Week 61615
Baseline to Week 101712
SecondaryChange From Baseline in in Clinical Global Impressions Scale (CGI-S)

The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness.

Time frame:
Baseline, Week 2, Week 6
Reported as:
Mean · units on a scale
Change From Baseline in in Clinical Global Impressions Scale (CGI-S)
units on a scaleArm 2- MM-120Arm 1- Placebo
Baseline for Week 24.9 ± 0.714.7 ± 0.62
Week 24.6 ± 0.704.3 ± 0.53
Baseline for Week 64.9 ± 0.734.8 ± 0.60
Week 64.0 ± 0.883.8 ± 0.85
SecondaryAdult Attention-deficit/Hyperactivity Disorder Self-reporting Rating Scale (ASRS)

The Adult Attention-Deficit/Hyperactivity Disorder Self-Reporting Rating Scale (ASRS) is composed of 18 questions, and uses a scale that ranges from 0-4 based on the individuals mark in either the "never, rarely, sometimes, often, very often" column for a possible total score of 72. A higher score corresponds to a worse severity of ADHD.

Time frame:
6 weeks
Reported as:
Mean · units on a scale
Adult Attention-deficit/Hyperactivity Disorder Self-reporting Rating Scale (ASRS)
units on a scaleArm 2- MM-120Arm 1- Placebo
Baseline for Week 248.0 ± 7.0143.9 ± 7.33
Week 240.2 ± 9.2636.7 ± 9.38
Baseline for Week 448.6 ± 7.6744.6 ± 7.61
Week 435.2 ± 8.1434.9 ± 9.29
Baseline for Week 6 (Day 36)48.4 ± 7.1044.2 ± 7.72
Week 6 (Day 36)36.0 ± 9.9933.1 ± 11.70
Baseline to Week 6 (Day 40)49.6 ± 6.9644.0 ± 7.86
Week 6 (Day 40)31.0 ± 9.1831.7 ± 12.0
SecondaryChange From Baseline in Connors' Adult ADHD Rating Scale (CAARS)

The Connors' Adult ADHD Rating Scale (CAARS) Self-Report Long Form is a 66-item measure of ADHD symptom. Responses are scored on a 4-point scale, where 0 = not at all, 1 = just a little, 2 = pretty much, and 3 = very much. Item scores are summed to three main scores which are then transformed using population-derived age- and sex-adjusted norm values to a T-score. A T-score \< 60 indicates no ADHD. A T-score of 60-64 indicates borderline ADHD. A T-score of \> 64 indicates ADHD.

Time frame:
6 weeks
Reported as:
Mean · units on a scale
Change From Baseline in Connors' Adult ADHD Rating Scale (CAARS)
units on a scaleArm 2- MM-120Arm 1- Placebo
Change from baseline to Week 2-4.0 ± 5.79-2 ± 3.29
Change from baseline to Week 4-6.9 ± 5.36-3.6 ± 4.4
Change from Baseline to Week 6 (Day 36)-5.6 ± 6-4.6 ± 5.1
Change from Baseline to Week 6 (Day 40)-6.3 ± 5.82-4.3 ± 5.98
Secondary5 Dimensions of Altered States of Consciousness Questionnaire (5D-ASC) Scores

The 5 dimensions of altered states of consciousness (5D-ASC) scale is a visual analog scale (VAS) consisting of 94 items each scored on a 0-100mm VAS extrapolated to 100% scale for quantitative evaluation. These 94 items are categorized into five dimensions: oceanic boundlessness (min:0, max:2700), anxious ego dissolution (min:0, max:2100), visionary destructuralization (min:0, max:1800), auditory alterations (min:0, max:1600), and vigilance reduction (min:0, max:1200). The total score is the sum of all questions and can range from 0 to 9400. Higher scores = more alteration in state of consciousness.

Time frame:
6 weeks
Reported as:
Mean · units on a scale
5 Dimensions of Altered States of Consciousness Questionnaire (5D-ASC) Scores
units on a scaleArm 2- MM-120Arm 1- Placebo
W1D1 Oceanic boundlessness479.6 (277.3 to 681.9)161.3 (26.2 to 296.4)
W1D1 Anxious ego dissolution103.6 (35.5 to 171.6)19.0 (5.9 to 32.2)
W1D1 Visionary destructuralization233.4 (135.6 to 331.2)94.8 (18.6 to 171.0)
W1D1 Auditory alterations71.0 (12.2 to 129.7)32.7 (1.6 to 63.8)
W1D1 Vigilance reduction288.5 (198.0 to 379.0)155.2 (79.3 to 231.1)
W1D1 Total score1176.0 (781.4 to 1570.6)463.0 (166.9 to 759.1)
W6 Oceanic boundlessness403.3 (194.3 to 612.4)70.2 (16.0 to 124.4)
W6 Anxious ego dissolution41.0 (-0.6 to 82.7)4.2 (-0.4 to 8.7)
W6 Visionary destructuralization199.7 (86.9 to 312.5)32.9 (6.4 to 59.4)
W6 Auditory alterations18.4 (0.2 to 36.7)4.2 (0.0 to 8.4)
W6 Vigilance reduction90.3 (52.2 to 128.5)20.0 (6.9 to 33.1)
W6 Total scores752.9 (387.2 to 1118.6)131.4 (50.0 to 212.8)
SecondaryMystical Experience Questionnaire 30 Items (MEQ30)

The Mystical Experience Questionnaire 30 item (MEQ30) is a 30-item questionnaire rated on a six-point scale. The scale has been used to assess mystical experiences in studies using psilocybin and LSD. Higher scores = greater mystical experiences. The total score is expressed as a percentage of the maximum possible score (0 to 100%).

Time frame:
6 weeks
Reported as:
Mean · percentage of maximum possible score
Mystical Experience Questionnaire 30 Items (MEQ30)
percentage of maximum possible scoreArm 2- MM-120Arm 1- Placebo
Week 1 Day 122.37 (14.57 to 30.17)10.40 (3.97 to 16.84)
Week 620.50 (11.94 to 29.06)5.20 (1.40 to 9.01)
SecondarySummary of Drug Effects Visual Analog Scale (VAS)

A series of single item visual Analog Scales (VAS) are used repeatedly 0 -6 hours after drug administration: The following 9 items were used in VAS (0-100 mm): "any drug effect", "good drug effect", bad drug effect", "drug liking", "fear", nausea", "alteration of vision", "alteration of sense of time", and "the boundaries between myself and my surroundings seem to blur". VAS scores range from 0 = no effect to 100 = strong effect. The scores for each item are extrapolated to a 100% scale and presented for each time point of assessment.

Time frame:
6 hours
Reported as:
Mean · percentage of maximum possible score
Summary of Drug Effects Visual Analog Scale (VAS)
percentage of maximum possible scoreArm 2- MM-120Arm 1- Placebo
0h Any drug effect0 (0 to 0)0 (0 to 0)
0h Drug liking37.1 (0 to 55)44.9 (0 to 52)
0h Fear2.7 (0 to 36)1.4 (0 to 23)
0h Nausea1.1 (0 to 30)0 (0 to 0)
0h Alteration of vision0 (0 to 0)0 (0 to 0)
0h Alteration of sense of time0 (0 to 0)0 (0 to 0)
0h Boundaries blur0 (0 to 0)0 (0 to 0)
0.5h Any drug effect8.9 (0 to 78)11.3 (0 to 75)
0.5h Drug liking44.4 (0 to 78)48.1 (0 to 83)
0.5h Fear2.0 (0 to 54)2.2 (0 to 48)
0.5h Nausea2.0 (0 to 53)0.2 (0 to 3)
0.5h Alteration of vision3.5 (0 to 54)7.4 (0 to 81)
0.5h Alteration of sense of time2.5 (0 to 41)3.2 (0 to 35)
0.5h Boundaries blur3.0 (0 to 71)0.8 (0 to 12)
1h Any drug effect24.1 (0 to 100)12.7 (0 to 64)
1h Drug liking49.7 (0 to 97)51.8 (2 to 97)
1h Fear1.4 (0 to 32)0.1 (0 to 2)
1h Nausea2.7 (0 to 37)1.0 (0 to 23)
1h Alteration of vision4.0 (0 to 56)6.9 (0 to 72)
1h Alteration of sense of time8.1 (0 to 73)6.3 (0 to 68)
1h Boundaries blur6.0 (0 to 87)1.5 (0 to 24)
2h Any drug effect38.1 (0 to 97)12.8 (0 to 72)
2h Drug liking57.3 (0 to 100)53.3 (3 to 100)
2h Fear4.1 (0 to 68)0.1 (0 to 2)
2h Nausea8.2 (0 to 60)0.1 (0 to 2)
2h Alteration of vision13.0 (0 to 84)6.2 (0 to 88)
2h Alteration of sense of time13.5 (0 to 78)4.4 (0 to 53)
2h Boundaries blur12.3 (0 to 83)1.3 (0 to 14)
3h Any drug effect44.3 (0 to 97)11.1 (0 to 65)
3h Drug liking61.6 (0 to 100)53.1 (3 to 96)
3h Fear2.9 (0 to 54)0.2 (0 to 2)
3h Nausea8.0 (0 to 56)0.2 (0 to 3)
3h Alteration of vision13.9 (0 to 84)6.5 (0 to 76)
3h Alteration of sense of time12.3 (0 to 89)4.9 (0 to 74)
3h Boundaries blur12.7 (0 to 88)1.4 (0 to 31)
4h Any drug effect38.5 (0 to 97)15.1 (0 to 100)
4h Drug liking60.7 (0 to 100)48.0 (2 to 100)
4h Fear2.7 (0 to 50)0.1 (0 to 2)
4h Nausea6.9 (0 to 65)0.1 (0 to 2)
4h Alteration of vision12.4 (0 to 86)3.2 (0 to 37)
4h Alteration of sense of time12.1 (0 to 92)7.0 (0 to 57)
4h Boundaries blur6.9 (0 to 69)0.2 (0 to 2)
6h Any drug effect16.7 (0 to 75)9.6 (0 to 72)
6h Drug liking54.8 (0 to 100)49.6 (0 to 100)
6h Fear2.3 (0 to 52)2.1 (0 to 48)
6h Nausea3.6 (0 to 52)0.2 (0 to 4)
6h Alteration of vision4.1 (0 to 59)5.8 (0 to 59)
6h Alteration of sense of time6.3 (0 to 69)3.0 (0 to 55)
6h Boundaries blur4.1 (0 to 61)0.1 (0 to 2)
Other pre-specifiedPharmacokinetic Outcomes

Maximum Plasma Concentration \[Cmax\] of MM-120 in the blood at Week 1 Day 1

Time frame:
0.5, 1, 2, 3, 4, 6 hours post-dose
Reported as:
Mean · ng/mL
Pharmacokinetic Outcomes
ng/mLArm 2- MM-120
Pre-dose (0 hours)0 ± 0
0.5hours0.3250 ± 0.16534
1hour0.4410 ± 0.15686
2hours0.4270 ± 0.12832
3hours0.3591 ± 0.12493
4hours0.3066 ± 0.10851
6hours0.2117 ± 0.09361
Other pre-specifiedPharmacokinetic Parameters (Cmax)

Maximum concentration (Cmax)

Time frame:
0.5, 1, 2, 3, 4, 6 hours post-dose
Reported as:
Mean · ng/mL
Pharmacokinetic Parameters (Cmax)
ng/mLArm 2- MM-120
Pharmacokinetic Parameters (Cmax)0.4811 ± 0.14279
Other pre-specifiedPharmacokinetic Parameters (Tmax and t1/2)

Time to maximum concentration (Tmax), half life (t1/2)

Time frame:
0.5, 1, 2, 3, 4, 6 hours post-dose
Reported as:
Mean · hours
Pharmacokinetic Parameters (Tmax and t1/2)
hoursArm 2- MM-120
Tmax1.46 ± 0.706
t1/23.8187 ± 1.27269
Other pre-specifiedPharmacokinetic Parameters (AUC0-inf and AUC0-6h)

Area under the concentration curve from time 0 to infinity (AUC0-inf), Area under the concentration curve from time 0 to 6 hour (AUC0-6h)

Time frame:
0.5, 1, 2, 3, 4, 6 hours post-dose
Reported as:
Mean · ng*h/mL
Pharmacokinetic Parameters (AUC0-inf and AUC0-6h)
ng*h/mLArm 2- MM-120
AUC0-inf3.2450 ± 1.58494
AUC0-6hr1.9411 ± 0.63490

Adverse events

Collected over From time of signing ICF (or screening visit) through study completion, typically 14 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 2- MM1200/27 (0%)0/27 (0%)21/27 (77.8%)
Arm 1- Placebo0/26 (0%)0/26 (0%)23/26 (88.5%)
Most frequent other events
Showing 10 of 55
Most frequent other events
EventArm 2- MM120Arm 1- Placebo
HeadacheNervous system disorders13/279/26
NasopharyngitisInfections and infestations3/275/26
NauseaGastrointestinal disorders5/271/26
IllusionPsychiatric disorders4/270/26
FatigueGeneral disorders4/271/26
InsomniaPsychiatric disorders3/271/26
Disturbance in AttentionNervous system disorders2/272/26
ApathyPsychiatric disorders1/272/26
Abdominal painGastrointestinal disorders1/272/26
FlatulenceGastrointestinal disorders2/270/26

Baseline characteristics

A summary of demographic information for the FAS is shown below.

Age, Continuous
Age, Continuous(years)Arm 2- MM120Arm 1- PlaceboTotal
Mean40.3 ± 12.833.1 ± 11.036.7 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Arm 2- MM120Arm 1- PlaceboTotal
Female13922
Male141731
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 2- MM120Arm 1- PlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported272653
Region of Enrollment
Region of Enrollment(participants)Arm 2- MM120Arm 1- PlaceboTotal
Netherlands213
Switzerland252550
Baseline ADHD investigator symptom rating scale (AISRS)
Baseline ADHD investigator symptom rating scale (AISRS)(units on a scale)Arm 2- MM120Arm 1- PlaceboTotal
Mean37.4 ± 6.1137.3 ± 5.2437.4 ± 5.69
08

Study locations

2 sites
  • Maastricht University
    Maastricht, Netherlands
  • University Hospital Basel
    Basel, Switzerland
09

References and documents

Publications

  • Haijen-Bongers ECHM, Hurks PPM, Schepers J, Vizeli P, Santos de Jesus J, Mueller L, Schmid Y, Liechti ME, Kuypers KPC. Effects of repeated low-dose LSD on neuropsychological functioning in adults with ADHD: a randomized placebo-controlled study. Psychopharmacology (Berl). 2026 Jun 20. doi: 10.1007/s00213-026-07107-7. Online ahead of print. PubMed 42322409 ↗
  • Mueller L, Santos de Jesus J, Schmid Y, Muller F, Becker A, Klaiber A, Straumann I, Luethi D, Haijen ECHM, Hurks PPM, Kuypers KPC, Liechti ME. Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults: A Randomized Clinical Trial. JAMA Psychiatry. 2025 Jun 1;82(6):555-562. doi: 10.1001/jamapsychiatry.2025.0044. PubMed 40105807 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Nov 2023, 22 months.

Results were first posted in Apr 2025, 1 year 5 months after primary completion.

Of 24 industry-sponsored phase 2 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 22 months is above that.

Counting every sponsor, half of 40 studies reached it within 15 months; a quarter within 5 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2021
First posted
Jan 21, 2022
StartActual
Dec 17, 2021
Primary completionActual
Nov 6, 2023
CompletionActual
Dec 4, 2023
Results first posted
Apr 13, 2025
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05200936
Lead sponsor
Definium Therapeutics US, Inc.
Responsible party
Sponsor
First posted
Jan 21, 2022
Start date
Dec 17, 2021
Primary completion
Nov 6, 2023
Completion
Dec 4, 2023
Results posted
Apr 13, 2025
Last update
Feb 27, 2026

Study contacts

Kim Kuypers
principal investigator · Maastricht University
Matthias Liechti
principal investigator · University Hospital, Basel, Switzerland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lysergide D-tartrate

Start the discussion